Patents by Inventor Jason Christopher Rech

Jason Christopher Rech has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018144
    Abstract: Provided herein are processes for synthesizing compounds useful as EGFR modulators.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 18, 2024
    Inventors: Jason Christopher Rech, Mukesh K. Nyati, Fan Fang, Lei Zhang, Julian Paul Henschke
  • Publication number: 20230097789
    Abstract: Provided herein are compounds that are useful in treating cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: March 30, 2023
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch, Alexander Bridges
  • Publication number: 20230098205
    Abstract: Provided herein are compounds that are useful in treating cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: March 30, 2023
    Inventors: Mukesh K. Nyati, Alexander Bridges, Jason Christopher Rech, Brennan Taylor Watch
  • Publication number: 20220340572
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Application
    Filed: May 9, 2022
    Publication date: October 27, 2022
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • Patent number: 11358965
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 14, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • Publication number: 20200377503
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Application
    Filed: February 25, 2019
    Publication date: December 3, 2020
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • Patent number: 8431704
    Abstract: The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I).
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 30, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Christopher John Love, Joseph Elisabeth Leenaerts, Ludwig Paul Cooymans, Donald Alec Lebsack, Bryan James Branstetter, Jason Christopher Rech, Elizabeth Ann Gleason, Jennifer Diane Venable, Danielle Wiener, Deborah Margaret Smith, James Guy Breitenbucher
  • Publication number: 20110092481
    Abstract: The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: April 21, 2009
    Publication date: April 21, 2011
    Inventors: Christopher John Love, Joseph Elisabeth Leenaerts, Ludwig Paul Cooymans, Donald Alec Labsack, Bryan James Branstetter, Jason Christopher Rech, Elizabeth Ann Gleason, Jennifer Diane Venable, Danielle Wiener, Deborah Margaret Smith, James Guy Breitenbucher